Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

458.24USD
24 May 2017
Change (% chg)

$-3.13 (-0.68%)
Prev Close
$461.37
Open
$461.37
Day's High
$461.46
Day's Low
$452.11
Volume
153,590
Avg. Vol
301,045
52-wk High
$464.38
52-wk Low
$325.62

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $49,039.30
Shares Outstanding(Mil.): 106.29
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 55.51 141.11 17.36
EPS (TTM): 8.31 -- --
ROI: 16.76 2.25 -5.72
ROE: 22.32 0.17 -5.10

UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

May 22 2017

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

May 22 2017

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.

May 22 2017

BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr

* Regeneron and sanofi announce fda approval of kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients

May 22 2017

Sanofi pegs U.S. drug price rises to below healthcare inflation

French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

May 09 2017

Sanofi pegs U.S. drug price rises to below healthcare inflation

French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.

May 09 2017

UPDATE 2-Sanofi pegs U.S. drug price rises to below healthcare inflation

* More transparency on gross and net prices in U.S. (Adds projection for NHE inflation rate, detail on Sanofi drugs)

May 09 2017

Sanofi, Regeneron hope LED case will shine a light on Praluent injunction appeal

Sanofi SA and Regeneron Pharmaceuticals Inc are citing a little-noticed federal appeals court ruling in a patent dispute over LED lights last month to bolster their own appeal of a court order banning sales of their cholesterol drug Praluent.

May 08 2017

BRIEF-Regeneron and Sillajen report immuno-oncology clinical study agreement

* Regeneron and Sillajen announce immuno-oncology clinical study agreement for combination treatment in kidney cancer

May 08 2017

BRIEF-Regeneron and Inovio enter immuno-oncology clinical study agreement

* Regeneron and Inovio enter immuno-oncology clinical study agreement for glioblastoma combination therapy

May 08 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.10 +0.05
Pfizer Inc. (PFE.N) $32.05 -0.09
Bayer AG (BAYGn.DE) €117.65 --
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.60 --
Merck & Co., Inc. (MRK.N) $64.93 +0.38
Amgen, Inc. (AMGN.OQ) $154.60 +0.53
Roche Holding Ltd. (ROG.S) CHF267.20 -0.70
Roche Holding Ltd. (RO.S) CHF267.50 +0.25
Eli Lilly and Co (LLY.N) $77.96 -0.03

Earnings vs. Estimates